RD
Insider
Robert W Duggan
DirectorRobert W Duggan (Director) filed 4 Form 4 reports in the trailing twelve months (4 purchases, 0 sales, 1 filed past the two-business-day deadline), most often in PLSE. Across 3 priced purchase filings, the average 21-session return was +19.8% from execution and +19.8% from disclosure (delay-adjusted; derived). The largest single filing was $50.0M of SMMT (3,810,000 sh × $13.12, as filed), executed Jun 12. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+19.8%
avg across 3 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+19.8%
same 3 filings, from disclosure
Filings, ttm
4
4 buys · 0 sells · 1 late
Median delay
0d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$77.4M
shares × price, as filed
Last traded
Jun 12
Filed Jun 12
Median ADV $66.4M across their filed names
Impact on $10,000 · 12M
$12,602 (+26.0%)
S&P 500 $10,907 (+9.1%) · 17.0 pts ahead
Robert W Duggan
S&P 500
Derived: compounded across filings from disclosure dates · past 12 months
Open performance→Volume by month
Buys $89.3M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Not on file
2 filings
Sector per market data · by filing · past 12 months
Most traded names
PLSE
PLSE
5 buys · 0 sells
5 filings
SMMT
Summit Therapeutics Inc.
SMMT · 4 buys · 0 sells
4 filings
PLES
PLES
1 buy · 0 sells
1 filing
Recent filings
PLSEPURCHASE
PULSE BIOSCIENCES, INC.
View filing →
$972K56,054 sh across 2 lots
Exec Dec 11 2024
Filed Dec 13 2024 · 5:30 PM ET PLSEPURCHASE PULSE BIOSCIENCES, INC. View filing → $2.8M
192,599 sh across 3 lots
Exec Sep 11 2024
Filed Sep 12 2025 · 8:14 PM ET †